{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=38", "query": { "intervention": "Part 1", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 6233, "total_pages": 624, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T18:16:50.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00796055", "title": "Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "MEDI-547", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-08", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2011-11-17", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Detroit, Michigan", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00796055" }, { "nct_id": "NCT03566043", "title": "CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mucopolysaccharidosis Type II (MPS II)" ], "interventions": [ { "name": "RGX-121", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "REGENXBIO Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "5 Years", "sex": "MALE", "summary": "4 Months to 5 Years · Male only" }, "enrollment_count": 48, "start_date": "2018-09-27", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 4, "location_summary": "Oakland, California • New Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03566043" }, { "nct_id": "NCT03461718", "title": "Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Administration and Dosage of Ketamine", "Endoscopic Sedation" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Midazolam injection", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brooke Army Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 66, "start_date": "2018-03-05", "completion_date": "2019-10-01", "has_results": false, "last_update_posted_date": "2020-07-08", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 1, "location_summary": "Fort Sam Houston, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03461718" }, { "nct_id": "NCT01427218", "title": "Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Heart Disease", "Myocardial Infarction" ], "interventions": [ { "name": "Titration of medications", "type": "OTHER" }, { "name": "Lifestyle Counseling", "type": "BEHAVIORAL" }, { "name": "Medication Counseling", "type": "BEHAVIORAL" }, { "name": "Usual Care with Medication Reconciliation", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Middle Tennessee Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 170, "start_date": "2010-11", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2011-09-01", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427218" }, { "nct_id": "NCT07201558", "title": "Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis", "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Surovatamig", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2025-12-02", "completion_date": "2028-06-27", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Allen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07201558" }, { "nct_id": "NCT05388435", "title": "Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "SKL27969", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SK Life Science, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-09-12", "completion_date": "2024-03-01", "has_results": false, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 4, "location_summary": "Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05388435" }, { "nct_id": "NCT02702960", "title": "Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma", "Hepatocellular Carcinoma (Fibrolamellar Variant)", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "living related donor partial liver transplantation", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Bone marrow transplant from same donor", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2018-01-03", "has_results": false, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702960" }, { "nct_id": "NCT01831804", "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Wound Healing" ], "interventions": [ { "name": "GSK1278863", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 65, "start_date": "2013-06-17", "completion_date": "2017-02-10", "has_results": true, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 7, "location_summary": "Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more", "locations": [ { "city": "Castro Valley", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01831804" }, { "nct_id": "NCT06702449", "title": "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Tract Infections" ], "interventions": [ { "name": "Candidate UTI vaccine low dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine low dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine medium dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine medium dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine high dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine high dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine HTD formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 448, "start_date": "2024-11-19", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 6, "location_summary": "Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Secaucus", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" }, { "city": "Weatherford", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06702449" }, { "nct_id": "NCT05807126", "title": "Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Magrolimab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-03-05", "completion_date": "2026-12-06", "has_results": false, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-11-13T18:16:50.600Z", "location_count": 5, "location_summary": "Costa Mesa, California • Orange, California • The Bronx, New York + 1 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05807126" } ] }